Alzamend Neuro Inc. released its quarterly financial results for the period ending July 31, 2025. The company did not report any revenue for this quarter, consistent with the same period in 2024, as its product candidates AL001 and ALZN002 are still in the clinical stage of development. The net loss per common share was reported at $1.28, based on a basic and diluted weighted average of 2.1 million common shares outstanding. This is a decrease compared to a net loss per common share of $11.42 in the previous period, which was based on a lower average of 85,314 common shares outstanding. The company does not anticipate generating revenue in the foreseeable future as its product candidates require extensive development, regulatory approval, and significant investment before they can be marketed.